2018
Implementing Liquid Biopsies in Clinical Trials
Lustberg M, Stover D, Chalmers J. Implementing Liquid Biopsies in Clinical Trials. The Cancer Journal 2018, 24: 61-64. PMID: 29601331, PMCID: PMC5880324, DOI: 10.1097/ppo.0000000000000309.Peer-Reviewed Original ResearchConceptsClinical trialsLiquid biopsyReal-time biopsySurrogate efficacy endpointsTreatment response evaluationMultiple clinical trialsRoutine clinical practiceCell-free DNATumor-specific biomarkersEfficacy endpointBlood markersPredictive biomarkersPharmacodynamic biomarkersPrognostic biomarkerTreatment selectionTumor markersBiopsyClinical practiceDisease statusTumor cellsResponse evaluationAdditional studiesBiomarkersTrialsExtracellular vesicles
2012
Microcirculatory fraction (MCFI) as a potential imaging marker for tumor heterogeneity in breast cancer
Yang X, Mrozek E, Lustberg M, Jia G, Sammet S, Sammet C, Shapiro C, Knopp M. Microcirculatory fraction (MCFI) as a potential imaging marker for tumor heterogeneity in breast cancer. Magnetic Resonance Imaging 2012, 30: 1059-1067. PMID: 22884756, PMCID: PMC3645932, DOI: 10.1016/j.mri.2012.04.026.Peer-Reviewed Original ResearchConceptsPotential imaging markerPathologic responseBreast cancerTumor heterogeneityImaging markerHER-2 negative breast cancerImaging biomarkersVolumetric biomarkersCombination neoadjuvant chemotherapyCurrent imaging studiesGood predictive biomarkerNegative breast cancerTherapeutic response assessmentNovel imaging biomarkersNeoadjuvant chemotherapyRetrospective studyPredictive biomarkersNovel biomarkersResponse assessmentHeterogeneous diseaseEarly changesImaging studiesBiomarkersCancerCellular composition